tirzepatide drug vs. Semaglutide: Which Weight Loss Medication Is Right for You? Zepbound (Tirzepatide) for Chronic Weight

In our patient, urinary retention may have been secondary to dysautonomia as a result of TIND

The AASM conditionally recommends myofunctional therapy as an adjunct rather than a standalone treatment

In the third sensitivity analysis, excluding patients using other types of glucagon-like peptide-1 receptor agonists, the use of once-weekly semaglutide still independently predicted a higher risk of upcoming NAION (multivariable adjusted HR 234, 95% CI 154 357), compared to non-semaglutide users in a multivariable model adjusted as in the first sensitivity analysis

Athletes and bodybuilders purchase the product on the black market, hoping it will be an even better solution for muscle growth enhancement than taking insulin-like growth factor 1 or hGH

Patient Assessment Protocol Comprehensive medical history with obesity-specific screening Physical examination including BMI, waist circumference, and body composition analysis Laboratory workup: complete metabolic panel, lipid panel, HbA1c, thyroid function, insulin levels Screening for sleep apnea, PCOS, Cushing syndrome, and other secondary causes of obesity Mental health screening for binge eating disorder and depression Readiness-to-change assessment Medication Formulary for Your Medical Weight Loss Program GLP-1 receptor agonists: Semaglutide (Wegovy), liraglutide (Saxenda), tirzepatide (Zepbound) Sympathomimetic agents: Phentermine (short-term), phentermine/topiramate (Qsymia) Other FDA-approved options: Naltrexone/bupropion (Contrave), orlistat (Xenical/Alli) Off-label considerations: Metformin, topiramate, bupropion (when clinically appropriate and properly documented) Your medical weight loss program's protocols should specify prescribing criteria, dosing escalation schedules, monitoring requirements, and discontinuation criteria for each medication

doi: 10.1016/j.semcdb.2017.05.023 3 MaNWangYLiXXuMTanD